QA-Bio

QA-Bio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

QA-Bio is a privately-held, commercial-stage company based in San Diego that supplies essential analytical tools for glycan characterization, a critical step in biopharmaceutical quality control. The company has established a global customer base, with its kits integrated into regulatory-approved manufacturing processes for biologics. Operating in the Diagnostics and Biologics sectors, QA-Bio generates revenue through the sale of its specialized reagent kits and related products to biopharma companies. Its value proposition centers on providing reliable, standardized tools that ensure accuracy and reproducibility in complex glycan analysis.

DiagnosticsBiologics

Technology Platform

Portfolio of optimized enzymatic and chemical reagent kits for glycan release, labeling, cleanup, and analysis, designed for accuracy and reproducibility in biopharmaceutical QC.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

Growth is driven by the expanding global biologics and biosimilars market, which requires mandatory glycan analysis for regulatory approval.
Opportunities exist in developing kits for next-generation therapeutics (ADCs, bispecifics, cell/gene therapies) and expanding geographic reach through established distributor networks in Asia and Europe.

Risk Factors

Risks include technological disruption from new analytical methods, competition from larger life science tools companies with broader portfolios, and reliance on the cyclical biopharmaceutical R&D and manufacturing sector.
Dependency on distributor relationships for international sales also presents an operational risk.

Competitive Landscape

QA-Bio competes in the niche glycan analysis reagent segment against the relevant divisions of large, diversified life science tools companies like Agilent, Thermo Fisher Scientific, and Merck KGaA. Its competitive advantage is deep specialization, proven use in regulatory submissions, and a focused product portfolio optimized for performance and ease-of-use.